Document Detail


Aristolochic acid-induced upper tract urothelial carcinoma in taiwan: Clinical characteristics and outcomes.
MedLine Citation:
PMID:  23292929     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Aristolochic acid (AA), a component of all Aristolochia-based herbal medicines, is a potent nephrotoxin and human carcinogen associated with upper urinary tract urothelial carcinoma (UUC). To investigate the clinical and pathological characteristics of AA-induced UUC, this study included 152 UUC patients, 93 of whom had been exposed to AA based on the presence of aristolactam-DNA adducts in the renal cortex. Gene sequencing was used to identify tumors with A:T-to-T:A transversions in TP53, a mutational signature associated with AA. Cases with both aristolactam-DNA adducts and A:T-to-T:A transversions in TP53 were defined as AA-UUC, whereas patients lacking both of these biomarkers were classified as non-AA-UUC. Cases with either biomarker were classified as possible-AA-UUC. Forty (26%), 60 (40%), and 52 (34%) patients were classified as AA-UUC, possible-AA-UUC, and non-AA-UUC, respectively. AA-UUC patients were younger (median ages: 64, 68, 68 years, respectively; p=0.189), predominately female (65%, 42%, 35%, respectively; p=0.011), had more end-stage renal disease (28%, 10%, 12%, respectively; p=0.055), and were infrequent smokers (5%, 22%, 33%, respectively; p=0.07) compared to possible-AA-UUC and non-AA-UUC patients. All 14 patients who developed contralateral UUC had aristolactam-DNA adducts; ten of these also had signature mutations. The contralateral UUC-free survival period was shorter in AA-UUC compared to possible- or non-AA-UUC (p=0.019 and 0.002, respectively), whereas no differences among groups were observed for bladder cancer recurrence. In conclusion, AA-UUC patients tend to be younger and female, and have more advanced renal disease. Notably, AA exposure was associated with an increased risk for developing synchronous bilateral and metachronous contralateral UUC. © 2013 Wiley Periodicals, Inc.
Authors:
Chung-Hsin Chen; Kathleen G Dickman; Chao-Yuan Huang; Masaaki Moriya; Chia-Tung Shun; Huai-Ching Tai; Kuo-How Huang; Shuo-Meng Wang; Yuan-Ju Lee; Arthur P Grollman; Yeong-Shiau Pu
Related Documents :
23380609 - Clinical characteristics and visual function tests with retinal tomographic correlation...
24433539 - The prevalence of migraine in restless legs syndrome.
24916929 - Total ige and eotaxin (ccl11) contents in tears of patients suffering from seasonal all...
24936119 - Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for ...
23340039 - Cortical sources of resting state eeg rhythms are sensitive to the progression of early...
23801879 - C-reactive protein and serum amyloid a overexpression in lung tissues of chronic obstru...
7697959 - D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable com...
2541809 - Abnormalities in the response of plasma arginine vasopressin during hypertonic saline i...
21308299 - Goldenhar syndrome: clinical features with orofacial emphasis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-7
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 UICC.
Affiliation:
Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or be...
Next Document:  CCN6: a novel method of aTAKing cancer.